Acrivon Therapeutics (NasdaqGM:ACRV) FY Conference Transcript

Acrivon Therapeutics FY Conference Summary Company Overview - Company: Acrivon Therapeutics (NasdaqGM:ACRV) - Focus: Development of precision medicine platforms and clinical assets, particularly in oncology Key Points Industry and Market Context - Endometrial Cancer: - Serous endometrial cancer accounts for 50% of all endometrial cancer mortality and is characterized by aggressive behavior and limited treatment options [9][10] - Current standard of care shows modest benefits, with a second-line treatment response rate of only 15% [10][14] Acrivon’s AP3 Platform - Platform Description: - A proteomics-based precision medicine platform utilizing generative AI to optimize drug discovery and clinical asset advancement [5][6] - Focused on pathway-based drug design to enhance efficacy and minimize survival pathways in cancer cells [6] Lead Asset: ACR-368 - Clinical Activity: - ACR-368, a dual CHK1/2 inhibitor, shows strong clinical activity in serous endometrial cancer, with a confirmed response rate of 44% in ongoing trials [19] - The drug is particularly effective in a patient population with limited treatment options, contributing to a significant unmet need [10][41] Clinical Trial Insights - Trial Structure: - Three arms in the ongoing trial: - Arm 1: Registrational intent for ACR-368 monotherapy in biomarker-positive patients - Arm 2: Exploratory arm assessing the contribution of ultra-low dose gemcitabine (ULDG) - Arm 3: New arm expanding the trial without the need for pretreatment biopsies, expected to enroll 90 patients by Q4 2026 [28][29] - Enrollment Strategy: - Rapid enrollment anticipated due to the use of serous subtype as a lineage biomarker, which simplifies patient selection [29] Efficacy and Safety Profile - Efficacy: - ACR-368 demonstrates a competitive response rate of approximately 50% in serous endometrial cancer, significantly higher than the standard of care [21][22] - Clinical benefit rate of 65% for patients maintaining stable disease for over 16 weeks [23] - Safety: - Favorable safety profile with minimal adverse events, primarily transient hematological issues [22][72] Future Development Plans - Phase 3 Trial: - A protocol for a Phase 3 trial has been submitted, focusing on the combination of ACR-368 with immunotherapy for enhanced efficacy [43] - New Targets: - Development of a CDK11 inhibitor, a potential first-in-class program, is underway with IND-enabling studies expected to conclude by the end of the year [78][80] Market Adoption and Physician Sentiment - Commercial Potential: - High enthusiasm from treating physicians, with expectations that 75% of second-line and 100% of third-line patients may be candidates for ACR-368 [40][41] - Unmet Need: - The significant unmet need in serous endometrial cancer is emphasized, with the potential for ACR-368 to fill a critical gap in treatment options [10][41] Conclusion Acrivon Therapeutics is positioned to address significant unmet needs in the oncology market, particularly in serous endometrial cancer, through its innovative AP3 platform and promising clinical assets like ACR-368. The company's strategic focus on rapid trial enrollment and favorable safety profiles enhances its potential for successful market adoption and regulatory approval.